Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments

IF 3.2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL Presse Medicale Pub Date : 2022-06-01 DOI:10.1016/j.lpm.2022.104144

Benjamin Chevalier , Arnaud Jannin , Stephanie Espiard , Emilie Merlen , Amandine Beron , Georges Lion , Marie-Christine Vantyghem , Damien Huglo , Christine Cortet-Rudelli , Clio Baillet

{"title":"Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments","authors":"Benjamin Chevalier , Arnaud Jannin , Stephanie Espiard , Emilie Merlen , Amandine Beron , Georges Lion , Marie-Christine Vantyghem , Damien Huglo , Christine Cortet-Rudelli , Clio Baillet","doi":"10.1016/j.lpm.2022.104144","DOIUrl":null,"url":null,"abstract":"<div>In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.</div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"51 2","pages":"Article 104144"},"PeriodicalIF":3.2000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Presse Medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0755498222000379","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 3

Abstract

In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

垂体腺瘤与核医学:最近的结果和正在进行的发展

为了探索垂体腺瘤(PA)，磁共振成像(MRI)仍然是基石。然而，有一些局限性，MRI可能不确定。核医学探查等其他影像学手段的发展可能有助于确认前列腺癌的诊断、指导治疗和随访。核医学使用放射性药物与单光子发射计算机断层扫描(SPECT)或正电子发射断层扫描(PET)结合CT扫描进行成像。放射性药物产品以特定的细胞元素为目标，可以探索几种生物途径。核医学也可用于治疗目的，本文将综述基于肽受体放射性核素疗法(PRRT)治疗侵袭性PA和垂体癌的最新进展。几种放射性示踪剂已经在PA的背景下进行了研究，本文的目的是讨论它们各自的性能和临床兴趣。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Presse Medicale 医学-医学：内科

自引率

3.70%

发文量

审稿时长

43 days

期刊介绍： Seule revue médicale "généraliste" de haut niveau, La Presse Médicale est l''équivalent francophone des grandes revues anglosaxonnes de publication et de formation continue. A raison d''un numéro par mois, La Presse Médicale vous offre une double approche éditoriale : - des publications originales (articles originaux, revues systématiques, cas cliniques) soumises à double expertise, portant sur les avancées médicales les plus récentes ; - une partie orientée vers la FMC, vous propose une mise à jour permanente et de haut niveau de vos connaissances, sous forme de dossiers thématiques et de mises au point dans les principales spécialités médicales, pour vous aider à optimiser votre formation.

期刊最新文献

Editorial board Contents Preventative and curative treatment of venous thromboembolic disease in cancer patients Elderly patients with venous thromboembolism: Insights from the RIETE registry Impact of thrombophilia on venous thromboembolism management